Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

S100A12 decreased SAA-induced ERK1/2 and MEK1/2 phosphorylation. by Yuen Ming Chung (406571)

KRAP−/− Mice Showed Decreased Weight-Gain and Decreased Adiposity. by Takahiro Fujimoto (268158)

Relative Aggrecan mRNA expression levels, as measured by qPCR, in lentiviral-transduced control cells and 5 AggKD cell lines confirm decreased Aggrecan expression in the AggKD cell... by Juanita K. Hodax (6848540)

HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching. by Michael Anthony Ruiz (726055)

“…[NG+control siRNA = 5mM D-glucose + 100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to U6 or β-actin and expressed as a fold change of NG+control siRNA].…”

Supplementary Material for: Longitudinal Decrease in Left Ventricular Size with Age: Impact on Mortality and Cardiovascular Hospitalization by figshare admin karger (2628495)

“…This study investigated clinical characteristics and outcomes associated with longitudinal decreases in LV size in this population. Methods: We analyzed echocardiographic data from 6,232 adults with normal baseline left ventricular end-diastolic diameter (LVEDD), with a mean interval of 4.8 years between baseline and follow-up echocardiograms. …”

Decreased cellular infiltration into lungs of <i>Ifi35</i> deficient mice after H5N1-VN/PR8 infection. by Anshu P. Gounder (626041)

Reduced RabGEF1 expression decreases NGF-induced TrkA phosphorylation but not TrkA internalization. by See-Ying Tam (828866)

Downregulation of LGR4 decreases ARPE-19 cell migration. by Qiang Hou (495704)

Supplementary Material for: Decreasing Attacks and Improving Quality of Life through a Systematic Management Program for Patients with Hereditary Angioedema by Nunes F.L. (10223465)

“…<b><i>Results:</i></b> Mean number of attacks/month significantly decreased (95% credible interval [CrI] excluding 0) from 1.15 preintervention to 0.25 and 0.23, 8 and 14 months within intervention, with mean decreases of −0.89 (95% CrI: −1.21 to −0.58) and −0.92 (95% CrI: −1.22 to −0.60), respectively. …”

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients by Anni A. Winckelmann (407551)

“…Furthermore, we measured HIV-specific antibodies, characterized T cell phenotypes and HIV-specific T cell immunity. We observed a mean reduction in proviral DNA in the CPG group of 12.6% (95% CI: −23.6–0.0) following each immunization whereas proviral DNA in the placebo-adjuvant group remained largely unchanged (6.7% increase; 95% CI: −4.2–19.0 after each immunization, p = 0.02). …”